This review discusses the evidence base, mechanism of action, and practical considerations for using sacubitril valsartan in patients with heart failure and reduced ejection fraction.
Answers are grounded in this paper and cite their sources.
Offers practical guidance on sacubitril valsartan in HFrEF; leaves open need for updated primary evidence synthesis.
Heart failure is a condition with high morbidity and mortality. Pharmacological treatment has greatly contributed to improved outcomes and experiences of people living with heart failure. A new agent, sacubitril valsartan, has been approved for patients with heart failure and reduced ejection fraction. This article discusses the evidence base, mechanism of action, clinical indications and practical considerations for the use of sacubitril valsartan in practice.
No takes yet. Share an insight, caveat, or question.
Emma Jane Brennan (2018) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: